TNFRSF1A and cancer: Furthermore, the combination treatment increased the expression of TNFR1, NIK, IKKα, and NFκB, encoding proteins responsible for activating the transcription of multiple pro-inflammatory cytokines and anti-apoptotic factors, potentially undermining the anticancer effects of the treatment and promoting cancer cell survival.